Close

Thermo Fisher Scientific (TMO) Tops Q4 EPS by 13c, Beats on Revenues

January 31, 2018 6:01 AM EST

Thermo Fisher Scientific (NYSE: TMO) reported Q4 EPS of $2.79, $0.13 better than the analyst estimate of $2.66. Revenue for the quarter came in at $6.05 billion versus the consensus estimate of $5.7 billion.

Fourth Quarter and Full Year 2017 Highlights

  • Fourth quarter revenue grew 22% to $6.05 billion.
  • Full year revenue grew 14% to $20.92 billion.
  • Fourth quarter GAAP diluted earnings per share (EPS) decreased 18% to $1.30.Full year GAAP diluted EPS increased 10% to $5.59. GAAP results include a one-time tax provision of $204 million associated with the recent enactment of tax reform legislation in the U.S.
  • Fourth quarter adjusted EPS increased 16% to $2.79.Full year adjusted EPS increased 15% to $9.49.
  • Invested $0.9 billion in R&D during the year and launched high-impact products across all segments, highlighted by the Thermo Scientific Q-Exactive HF-X mass spectrometer, Thermo Scientific Krios G3i cryo transmission electron microscope, Applied Biosystems SeqStudio genetic analyzer and the Oncomine Dx Target Test.
  • Delivered strong year-over-year growth in Asia-Pacific and Emerging Markets, led by outstanding performance in China, and added new capabilities to support growth opportunities in China, South Korea and the Middle East.
  • Deployed $7.8 billion in 2017 on strategic acquisitions, adding leading biopharma contract development and manufacturing services through Patheon and expanding our offerings in bioproduction, cloud-based informatics, electron microscopy and transplant diagnostics.
  • Returned $1 billion of capital to shareholders in 2017 through stock buybacks and dividends.

For earnings history and earnings-related data on Thermo Fisher Scientific (TMO) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Earnings, Guidance

Related Entities

Earnings